Exelixis
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Study of XL820 in Adults With Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00129571
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath